SRSF2 overexpression induces transcription-/replication-dependent DNA double-strand breaks and interferes with DNA repair pathways to promote lung tumor progression
Open Access
- 2 April 2025
- journal article
- Published by Oxford University Press (OUP) in NAR Cancer
- Vol. 7 (2) , zcaf011
Abstract
SRSF2 (serine/arginine-rich splicing factor 2) is a critical regulator of pre-messenger RNA splicing, which also plays noncanonical functions in transcription initiation and elongation. Although elevated levels of SRSF2 are associated with advanced stages of lung adenocarcinoma (LUAD), the mechanisms connecting SRSF2 to lung tumor progression remain unknown. We show that SRSF2 overexpression increases global transcription and replicative stress in LUAD cells, which correlates with the production of DNA damage, notably double-strand breaks (DSBs), likely resulting from conflicts between transcription and replication. Moreover, SRSF2 regulates DNA repair pathways by promoting homologous recombination and inhibiting nonhomologous end joining. Mechanistically, SRSF2 interacts with and enhances MRE11 (meiotic recombination 11) recruitment to chromatin, while downregulating 53BP1 messenger RNA and protein levels. Both events are likely contributing to SRSF2-mediated DNA repair process rerouting. Lastly, we show that SRSF2 and MRE11 expression is commonly elevated in LUAD and predicts poor outcome of patients. Altogether, our results identify a mechanism by which SRSF2 overexpression promotes lung cancer progression through a fine control of both DSB production and repair. Finally, we show that SRSF2 knockdown impairs late repair of ionizing radiation-induced DSBs, suggesting a more global function of SRSF2 in DSB repair by homologous recombination.Keywords
Funding Information
- Institut National de la Santé et de la Recherche Médicale
- Centre National de la Recherche Scientifique
- Univ. Grenoble Alpes
- Fondation ARC (PJA 2014-1201788)
- Comités Départementaux Allier, Isère and Savoie de la Ligue Nationale contre le Cancer
- Cancéropôle Ile de France (PLBIO-2014-08, INCA_16730)
- Région Auvergne-Rhône-Alpes
- Espoir Isère contre le cancer
- GEFLUC Grenoble
- INCa-PLBIO (INCa-PLBIO#2016-155)
- ERiCAN (DS-2018-0015)
- Canceropôle CLARA (PID2019-104195G)
- Spanish Ministry of Science and Innovation
- Agencia Estatal de Investigación (MSCA-IF-2017)
- Junta de Andalucía
- Institut National Du Cancer (INCA_16730, INCA_19472)
- Fondation pour la Recherche Médicale (DEQ20170839117, FDT202404018232)
- Fondation ARC (ARCPJA2023090007177)
- Fondation de France (00097702, 00113878, 00119148)
- La Ligue Nationale Contre le Cancer (IP/SC/SK-17250)
This publication has 88 references indexed in Scilit:
- The splicing factor SC35 has an active role in transcriptional elongationNature Structural & Molecular Biology, 2008
- Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation studyNature Medicine, 2008
- A forward chemical genetic screen reveals an inhibitor of the Mre11–Rad50–Nbs1 complexNature Chemical Biology, 2008
- ATM and ATR promote Mre11 dependent restart of collapsed replication forks and prevent accumulation of DNA breaksThe EMBO Journal, 2006
- Inactivation of the SR Protein Splicing Factor ASF/SF2 Results in Genomic InstabilityCell, 2005
- Activation of the DNA damage checkpoint and genomic instability in human precancerous lesionsNature, 2005
- DNA damage response as a candidate anti-cancer barrier in early human tumorigenesisNature, 2005
- Nbn heterozygosity renders mice susceptible to tumor formation and ionizing radiation-induced tumorigenesis.2003
- Cotranscriptionally Formed DNA:RNA Hybrids Mediate Transcription Elongation Impairment and Transcription-Associated RecombinationMolecular Cell, 2003
- Cancer predisposition and hematopoietic failure in Rad50S/S miceGenes & Development, 2002